Physician profile
Gregory Phillip Root
NPI 1467748889
$1,928.51
in general payments reported to CMS, 2019-2025
25 companies · $458 in 2025
The $458 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $82.72 · 2022: $204 · 2023: $276 · 2024: $477 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $331.21 | 2022-2025 | Nexplanon, Nuvaring |
| Intuitive Surgical, INC. | $325.62 | 2019-2024 | |
| Abbvie INC. | $237.44 | 2019-2022 | |
| Hologic Sales and Service, LLC | $180.86 | 2019-2025 | Thinprep 2000 Processor, Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $133.80 | 2019-2024 | |
| Astellas Pharma US INC | $86.51 | 2022-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $82.97 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $59.91 | 2020-2025 | Gardasil 9 |
| Sumitomo Pharma America, INC. | $52.59 | 2025 | Myfembree |
| Sage Therapeutics, LLC | $51.84 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $46.78 | 2024-2025 | Slynd, Tyblume |
| Minerva Surgical, INC | $36.95 | 2023 | |
| Innovation Technologies INC | $34.18 | 2022 | |
| Roche Diagnostics Corporation | $32.76 | 2019 | |
| Ethicon US, LLC | $32.29 | 2023 | Enseal |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.74 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $25.45 | 2025 | Monoferric |
| Therapeuticsmd, INC. | $23.59 | 2019 | |
| Mission Pharmacal Company | $22.94 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $21.40 | 2025 | Exparel |
| Millicent US INC | $17.50 | 2025 | Femlyv |
| Mycovia Pharmaceuticals, INC. | $16.21 | 2023 | Vivjoa |
| Coopersurgical, INC. | $15.90 | 2020 | |
| Avion Pharmaceuticals | $14.62 | 2019 | |
| Allergan, INC. | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Root listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.